Janka Held-Feindt

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 3

Top Topics

Natural Killer Cells

Replacement Therapy

Top Venues

Journal of cancer research and clinical oncology

Cytometry. Part B, Clinical cytometry

This page only lists publications with an associated author ORCID identifier.

Publications

Guranda Chitadze, Marcus Lettau, Christian Peters, Stefanie Luecke, Charlotte Flüh, Elgar Susanne Quabius, Michael Synowitz, Janka Held-Feindt, Dieter Kabelitz
Erroneous expression of NKG2D on granulocytes detected by phycoerythrin-conjugated clone 149810 antibody. Cytometry. Part B, Clinical cytometry (2021)
Moiken Mehner, Carolin Kubelt, Vivian Adamski, Christina Schmitt, Michael Synowitz, Janka Held-Feindt
Combined treatment of AT101 and demethoxycurcumin yields an enhanced anti-proliferative effect in human primary glioblastoma cells. Journal of cancer research and clinical oncology 146 (1) (2019)
Vivian Adamski, Christina Schmitt, Florian Ceynowa, Rainer Adelung, Ralph Lucius, Michael Synowitz, Kirsten Hattermann, Janka Held-Feindt
Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model. Journal of cancer research and clinical oncology 144 (8) (2018)